'Surprise' Bydureon Thumbs Up in Europe; Amylin Shares Rise
By Jennifer Boggs
Monday, April 18, 2011
Bydureon watchers finally got some good news, as the European Committee for Medicinal Products for Human Use (CHMP) voted in favor of the once-weekly version of glucagon-like peptide-1 agonist exenatide in Type II diabetes, all but ensuring the drug's final approval overseas.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.